Merck reported positive results for its experimental treatment designed to protect infants from RSV. The mid to late-stage trial showed the treatment reduced RSV-related hospitalizations by over 80% and lower respiratory infections by 90% compared to a placebo in infants through five months. The treatment also reduced lower respiratory infections requiring medical attention by more than 60%. Merck plans to discuss the data with regulators, aiming for availability by the 2025 to 2026 RSV season.
